Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,518 across all filing types
Latest filing 2024-08-02 Transaction in Own Shar…
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2024
Transaction in Own Shares Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 July 2024. It details movements in issued shares, treasury shares, share options, repurchases, and other share capital changes. It is submitted to the Hong Kong Exchanges and Clearing Limited and includes specific data on share repurchases and share option schemes. The document is a regulatory submission focused on share capital movements and share repurchase activities, not a financial report, earnings release, or management discussion. It fits best under the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares (share repurchase/issuance). The document length and content confirm it is a full report, not just an announcement or certification.
2024-08-02 English
CONTINUING CONNECTED TRANSACTIONS - PURSUANT TO RULE 14A.60(1) OF THE LISTING RULES
Regulatory Filings Classification · 95% confidence The document is an announcement made pursuant to Rule 14A.60(1) of the Listing Rules of the Hong Kong Stock Exchange. It discusses continuing connected transactions under a Consolidated Services Agreement between a non wholly-owned subsidiary of the company and a connected person. The document details the terms of the agreement, pricing, reasons for the agreement, and compliance with listing rules. It is an announcement about continuing connected transactions and compliance with regulatory requirements rather than a full financial report or audit. It does not contain financial statements or detailed financial analysis. The document is not a report publication announcement since it contains substantive information about the transaction itself. The content fits best under Regulatory Filings (RNS) as it is a regulatory announcement about connected transactions and compliance with listing rules, which is a typical use of the RNS category for miscellaneous regulatory disclosures that do not fit other categories.
2024-07-25 English
VOLUNTARY ANNOUNCEMENT - mRNA RSV VACCINE (SYS6016) OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the clinical trial approval of their mRNA RSV vaccine product. It is an announcement of a regulatory milestone and does not contain financial data, management discussion, or detailed report content. The document is relatively short (2791 characters) and serves as a public disclosure of a significant event rather than a financial or management report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing in the strict sense of compliance documents but rather a voluntary announcement about a product development milestone. Given the nature and content, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other specific categories.
2024-07-11 English
NEXT DAY DISCLOSURES RETURNS
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares, including share buybacks and cancellations. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) and provides detailed data on share repurchases and cancellations with dates and prices. The document is a regulatory disclosure about share repurchase activities and changes in capital structure rather than a financial report or earnings release. It is not a full report but a regulatory announcement of share capital changes. This fits the definition of a Share Issue/Capital Change (SHA) filing, which covers announcements regarding new share issues, stock splits, or other capital changes such as share repurchases and cancellations. The document length (7328 characters) and detailed tabular data support it being a substantive disclosure rather than a brief announcement or certification. Therefore, the correct classification is SHA with high confidence.
2024-07-11 English
VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE SYS6023 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the approval of a clinical trial application (IND) by the U.S. FDA for a new drug candidate. It is an announcement of a regulatory milestone related to clinical trials, not a financial report, management change, or shareholder meeting material. The document is short (2396 characters) and serves as a news update rather than a detailed report. It does not contain financial data, voting results, or detailed governance information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-07-08 English
VOLUNTARY ANNOUNCEMENT - ROXADUSTAT CAPSULES OBTAIN DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the drug registration approval of Roxadustat Capsules. It is a short announcement (2701 characters) and does not contain financial data, financial statements, or detailed report content. It is not an annual report, interim report, earnings release, or any detailed financial or management report. It is also not a regulatory filing in the sense of officer certifications or compliance documents. The announcement is about a product approval, which is a corporate news update. Given the content and length, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories.
2024-07-05 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.